Targeted therapy with the antibody-drug conjugate sacituzumab-govitecan as a promising treatment strategy for head and neck squamous cell carcinoma

Introduction Systemic treatment of head and neck squamous cell carcinoma (HNSCC) is based on chemotherapy, anti-PD-1 immunotherapy and EGFR inhibition. New targeted therapies with antibody-drug conjugates (ADC) have improved progression-free and overall survival in other oncological entities, such as the ADC sacituzumab govitecan (SG) directed against the cell surface antigen TROP2 in metastatic triple-negative breast cancer. There is evidence that HNSCC tumors express TROP2 and other ADC targets.